Tempest Therapeutics
Company Details
Status: Public
Employees: 11-50
Location:
2000 Sierra Point Pkwy, Suite 400, Brisbane, California 94005, US
Type:
sample
Technology:
sample
About: Tempest Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative small molecule therapeutics for cancer treatment. The company aims to create novel therapies that target tumor cells and activate tumor-specific immunity, providing meaningful benefits to patients. Founded in 2011, Tempest is supported by a team of experienced professionals in oncology drug discovery and development.
The company specializes in first-in-class small molecule product candidates. Key products include Amezalpat (TPST-1120), which is currently in a global Phase Ib/II trial for advanced or metastatic hepatocellular carcinoma, and TPST-1495, a dual antagonist of EP2 and EP4 receptors, planned for a Phase 2 study in patients with Familial Adenomatous Polyposis (FAP). Tempest Therapeutics collaborates with research networks and institutions, such as the National Cancer Institute, to advance its clinical programs. The company is listed on NASDAQ under the ticker symbol TPST and is based in Brisbane, California.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Tempest Therapeutics | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.